Suppr
超能文献

Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.

出版信息

Med Lett Drugs Ther. 2018 Mar 26;60(1543):53-55.

PMID:29635265

Abstract

摘要

相似文献

Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.

Med Lett Drugs Ther. 2018 Mar 26;60(1543):53-55.

Bilateral Subretinal Voretigene Neparvovec-rzyl (Luxturna) Gene Therapy.

Ophthalmol Retina. 2019 May;3(5):450. doi: 10.1016/j.oret.2019.02.007.

Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.

Mol Diagn Ther. 2020 Aug;24(4):487-495. doi: 10.1007/s40291-020-00475-6.

Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.

Ophthalmology. 2019 Sep;126(9):1273-1285. doi: 10.1016/j.ophtha.2019.06.017. Epub 2019 Jun 22.

Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.

Mol Ther. 2021 Feb 3;29(2):442-463. doi: 10.1016/j.ymthe.2020.11.029. Epub 2020 Dec 3.

Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.

Lancet. 2017 Aug 26;390(10097):849-860. doi: 10.1016/S0140-6736(17)31868-8. Epub 2017 Jul 14.

Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl.

Cold Spring Harb Perspect Med. 2023 May 2;13(5):a041307. doi: 10.1101/cshperspect.a041307.

Emerging Gene Therapy Treatments for Inherited Retinal Diseases.

Ophthalmic Surg Lasers Imaging Retina. 2018 Jul 1;49(7):472-478. doi: 10.3928/23258160-20180628-02.

Luxturna: FDA documents reveal the value of a costly gene therapy.

Drug Discov Today. 2019 Apr;24(4):949-954. doi: 10.1016/j.drudis.2019.01.019. Epub 2019 Jan 31.

Quantitative Autofluorescence Following Gene Therapy With Voretigene Neparvovec.

JAMA Ophthalmol. 2020 Aug 1;138(8):919-921. doi: 10.1001/jamaophthalmol.2020.2018.

引用本文的文献

Retinal gene therapy using epiretinal AAV-containing fibrin hydrogel implants.

Sci Adv. 2025 Sep 5;11(36):eadv7922. doi: 10.1126/sciadv.adv7922.

Addressing Challenges in Developing Treatments for Inherited Retinal Diseases: Recommendations From the Third Monaciano Symposium.

Transl Vis Sci Technol. 2025 Aug 1;14(8):37. doi: 10.1167/tvst.14.8.37.

Mannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency.

Mol Ther Methods Clin Dev. 2024 Jan 17;32(1):101187. doi: 10.1016/j.omtm.2024.101187. eCollection 2024 Mar 14.

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer's disease.

Life Sci Soc Policy. 2020 Oct 12;16(1):11. doi: 10.1186/s40504-020-00106-2.

Successful gene therapy requires targeting the vast majority of cancer cells.

Cancer Biol Ther. 2020 Oct 2;21(10):946-953. doi: 10.1080/15384047.2020.1809912. Epub 2020 Sep 30.

GPR108 Is a Highly Conserved AAV Entry Factor.

Mol Ther. 2020 Feb 5;28(2):367-381. doi: 10.1016/j.ymthe.2019.11.005. Epub 2019 Nov 13.

RPGR gene therapy presents challenges in cloning the coding sequence.

Expert Opin Biol Ther. 2020 Jan;20(1):63-71. doi: 10.1080/14712598.2020.1680635. Epub 2019 Oct 20.

Dual -AAV Vector Treatment Reduces Pathogenic Retinal A2E Accumulation in a Mouse Model of Autosomal Recessive Stargardt Disease.

Hum Gene Ther. 2019 Nov;30(11):1361-1370. doi: 10.1089/hum.2019.132. Epub 2019 Sep 30.

Current Approaches to Low Vision (Re)Habilitation.

Turk J Ophthalmol. 2019 Jun 27;49(3):154-163. doi: 10.4274/tjo.galenos.2018.53325.

Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.

PLoS One. 2019 Mar 21;14(3):e0212811. doi: 10.1371/journal.pone.0212811. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译